| Document Date: 2014-03-13 10:29:52
Open Document File Size: 510,21 KBShare Result on Facebook
Company IATT Paediatric Working Group / ID KG / ABC / FDC / / Country Ukraine / South Africa / India / / Event FDA Phase / / IndustryTerm 3TC 10mg/ml oral solution / 10mg/ml oral solution / HIV therapy / manufacturing / mg/ml oral solution / / MedicalCondition HIV / infection / / Organization World Health Organization / WHO PQ / TDF / FDA / Federal Trade Commission / UNAIDS / / Position GENERAL INFORMATION CLINICAL PRIORITISATION MARKET/IP PRIORITISATION First / GENERAL INFORMATION CLINICAL PRIORITISATION MARKET/IP PRIORITISATION / / Product EFAVIRENZ / 600mg / 150mg / 3TC 150mg / 3TC 30/60mg / 50mg / 3TC 600/300mg / 3TC+EFV 300/150+600mg / 25mg / NEVIRAPINE / ABACAVIR / 300mg / LAMIVUDINE / Paediatric / 75mg / 400mg / 200mg / WHO / AZT / / PublishedMedium the WHO / /
SocialTag |
Annex II - Product Cards The product cards below include details on the clinical and market/IP assessment for each ARV. For ARVs included in the WHO treatment guidelines, clinical information summarises their position i